It is my pleasure to present the latest issue of Myeloma with important news for you about our ongoing work to treat and extend the lives of those living with multiple myeloma. Since joining the Winthrop P. Rockefeller Cancer Institute in 2019, it has been my honor to work alongside the remarkable faculty and staff of the Myeloma Center. Under the leadership of Frits van Rhee, M.D., Ph.D., the Myeloma Center’s reputation as the world’s leader in myeloma treatment and research is well deserved.
As we pursue National Cancer Institute (NCI) Designation, our focus on research and clinical trials is paramount. This work is essential to improve treatment for all cancer patients and is bearing fruit for myeloma. In the past year alone, we’ve seen life-saving advancements, including the arrival of CAR T-cell therapy and the opening of our new Infusion Center and first Phase 1 Cancer Clinical Trial Unit.
The cover story featuring Frank Zhan, M.D., Ph.D., shares exciting news about his research to study the molecular genetics and drug resistance in multiple myeloma patients. Also featured are some of our dedicated staff members and stories of resilient survivors.
As we press on toward our goal of achieving NCI Designation, our Myeloma Center and other cancer programs will only grow in their impact on patient’s lives. I thank you for your support of our work.
Michael Birrer, M.D., Ph.D.
Vice Chancellor, UAMS
Director, Winthrop P. Rockefeller Cancer Institute
Director, Cancer Service Line